Align Technology, Inc. (NASDAQ:ALGN) Shares Purchased by Fulcrum Capital LLC

Fulcrum Capital LLC increased its stake in shares of Align Technology, Inc. (NASDAQ:ALGN) by 5.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,212 shares of the medical equipment provider’s stock after purchasing an additional 489 shares during the period. Fulcrum Capital LLC’s holdings in Align Technology were worth $1,921,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of ALGN. Baker Avenue Asset Management LP acquired a new position in Align Technology in the 3rd quarter valued at $4,250,000. Swedbank AB raised its holdings in Align Technology by 30.1% in the 3rd quarter. Swedbank AB now owns 389,115 shares of the medical equipment provider’s stock valued at $98,960,000 after acquiring an additional 90,000 shares during the last quarter. KBC Group NV raised its holdings in Align Technology by 11.8% in the 3rd quarter. KBC Group NV now owns 53,458 shares of the medical equipment provider’s stock valued at $13,595,000 after acquiring an additional 5,663 shares during the last quarter. Nordea Investment Management AB raised its holdings in Align Technology by 3.5% in the 4th quarter. Nordea Investment Management AB now owns 273,664 shares of the medical equipment provider’s stock valued at $56,870,000 after acquiring an additional 9,139 shares during the last quarter. Finally, Fisher Asset Management LLC raised its holdings in Align Technology by 2.6% in the 3rd quarter. Fisher Asset Management LLC now owns 105,770 shares of the medical equipment provider’s stock valued at $26,900,000 after acquiring an additional 2,717 shares during the last quarter. 88.43% of the stock is currently owned by institutional investors and hedge funds.

Align Technology Trading Up 0.5 %

ALGN traded up $1.01 on Monday, hitting $213.13. 265,345 shares of the company’s stock were exchanged, compared to its average volume of 622,663. The stock has a fifty day moving average of $222.25 and a two-hundred day moving average of $228.95. Align Technology, Inc. has a twelve month low of $196.09 and a twelve month high of $335.40. The firm has a market cap of $15.91 billion, a PE ratio of 36.37, a P/E/G ratio of 6.20 and a beta of 1.67.

Align Technology (NASDAQ:ALGN) last posted its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $2.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.31 by $0.04. The business had revenue of $977.87 million during the quarter, compared to analysts’ expectations of $990.05 million. Align Technology had a net margin of 11.15% and a return on equity of 13.99%. The business’s revenue was up 1.8% on a year-over-year basis. During the same period last year, the firm posted $1.62 earnings per share. On average, analysts predict that Align Technology, Inc. will post 7.45 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on ALGN shares. Mizuho started coverage on shares of Align Technology in a research note on Wednesday, December 4th. They set an “outperform” rating and a $295.00 price objective for the company. StockNews.com raised shares of Align Technology from a “hold” rating to a “buy” rating in a research note on Thursday, September 19th. Bank of America boosted their price objective on shares of Align Technology from $200.00 to $206.00 and gave the company an “underperform” rating in a research note on Friday, December 13th. Morgan Stanley lowered their price objective on shares of Align Technology from $310.00 to $280.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. Finally, Leerink Partnrs raised shares of Align Technology from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 6th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $268.20.

Align Technology Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.